Dottorato in BIOTECNOLOGIE MEDICO-CHIRURGICHE E MEDICINA TRASLAZIONALE

email: pamela.bielli@uniroma2.it
telefono: 001838

Curriculum vitae
Nome e Cognome Pamela Bielli
e-mail pamela.bielli@uniroma2.it

Educazione
2004 Conseguimento Esame di Stato abilitante alla Professione di biologo
2002 Conseguimento Dottorato di Ricerca, Università degli Studi di Roma “Roma Tre”, Roma, Italia
1998 Laurea in Scienze Biologiche (110/110 cum laude), Università degli Studi di Roma “Roma Tre”, Roma, Italia

Posizioni
2019-to date Professore Associato, Dipartimento di biomedicine e Prevenzione, Cattedra di Anatomia Umana, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma “Tor Vergata”, Roma, Italia;
2016-2019 Ricercatore a tempo determinato (RTD-B) Dipartimento di biomedicine e Prevenzione, Cattedra di Anatomia Umana, Facoltà di Medicina e Chirurgia, Università degli Studi di Roma “Tor Vergata”, Roma, Italia;
2012-2016 Ricercatore all’IRCCS Fondazione Santa Lucia, Roma, Italia;
2007-2011 Assegno di Ricerca, Dipartimento di Sanità Pubblica e Biologia Cellulare, Università degli Studi di Roma “Tor Vergata”, Roma, Italia;
2006-2007 Borsa di Studio, Ospedale Pediatrico “Bambino Gesù”, Roma, Italia;
2003-2005 Borsa di Studio, Istituto Pasteur- Fondazione Cenci-Bolognetti, Dipartimento di Biologia Cellulare e dello Sviluppo, Università degli Studi di Roma “La Sapienza”, Roma, Italia;
2002-2003 Borsa di Studio per ricercatori all’estero, Consiglio Nazionale delle Ricerche, Istituto di Microbiologia e Genetica, “Vienna Biocenter”, Università di Vienna, Vienna, Austria;
2000-2002 Contratto di Ricerca, Istituto di Microbiologia e Genetica, “Vienna Biocenter”, Università di Vienna, Vienna, Austria;
1998-2001 Dottorato di ricerca, Università degli Studi di Roma “Roma Tre”, Roma, Italia.

Finanziamenti
2022 “Exploiting splicing inhibition to overcome transcriptional addiction in prostate cancer” AIRC (IG27896)
2014 “Role of Alternative Polyadenylation in prostate cancer” Italian Ministry of Health “Giovani Ricercatori- Ricerca Finalizzata 2011-2012” (GR-2011-02348423).

Insegnamento
2021 to date Anatomia Umana, Università Medica Internazionale “UniCamillus” Roma, Italia;
2016 to date Anatomia Umana, Università degli Studi di Roma “Tor Vergata”, Roma, Italia
2002 Tutor in Genetica Molecolare e Patologica, Istituto di Microbiologia e Genetica, “Vienna Biocenter”, Università di Vienna, Vienna, Austria;
2001 Tutor in Genetica sperimenta (Genetica molecolare), Istituto di Microbiologia e Genetica, “Vienna Biocenter”, Università di Vienna, Vienna, Austria.

Pubblicazioni
1. Naro C, Antonioni A, Medici V, Caggiano C, Jolly A, de la Grange P, Bielli P, Paronetto MP, Sette C. (2024) Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer. J Exp Clin Cancer Res. 43(1):58. doi: 10.1186/s13046-024-02986-0.
2. Pieraccioli M, Caggiano C, Mignini L, Zhong C, Babini G, Lattanzio R, Di Stasi S, Tian B, Sette C, Bielli P. (2022) The transcriptional terminator XRN2 and the RNA-binding protein Sam68 link alternative polyadenylation to cell cycle progression in prostate cancer. Nat Struct Mol Biol. 29(11):1101-1112.
3. Caggiano C, Pieraccioli M, Pitolli C, Babini G, Zheng D, Tian B, Bielli P, Sette C. (2022) The androgen receptor couples promoter recruitment of RNA processing factors to regulation of alternative polyadenylation at the 3' end of transcripts. Nucleic Acids Res. 50(17):9780-9796.
4. Stagni V, Orecchia S, Mignini L, Beji S, Antonioni A, Caggiano C, Barilà D, Bielli P, Sette C. (2022) DNA Damage Regulates the Functions of the RNA Binding Protein Sam68 through ATM-Dependent Phosphorylation. Cancers (Basel). 9;14(16):3847.
5. Barchi M, Bielli P, Dolci S, Rossi P, Grimaldi P. (2021) Non-Coding RNAs and Splicing Activity in Testicular Germ Cell Tumors. Life (Basel) 11(8):736.
6. Naro C, Bielli P, Sette C. (2021) Oncogenic dysregulation of pre-mRNA processing by protein kinases: challenges and therapeutic opportunities. FEBS J. 288(21):6250-6272.
7. Caggiano C, Guida E, Todaro F, Bielli P, Mori M, Ghirga F, Quaglio D, Botta B, Moretti F, Grimaldi P, Rossi P, Jannini EA, Barchi M, Dolci S. (2020) Sempervirine inhibits RNA polymerase I transcription independently from p53 in tumor cells. Cell Death Discov. 28; 6(1):111.
8. Cesari E, Loiarro M, Naro C, Pieraccioli M, Farini D, Pellegrini L, Pagliarini V, Bielli P, Sette C. (2020) Combinatorial control of Spo11 alternative splicing by modulation of RNA polymerase II dynamics and splicing factor recruitment during meiosis. Cell Death Dis. Apr 17;11(4):240.
9. Pagliarini V, Jolly A, Bielli P, Di Rosa V, De la Grange P, Sette C. (2020) Sam68 binds Alu-rich introns in SMN and promotes pre-mRNA circularization. Nucleic Acids Res. 48(2):633-645.
10. Bielli P, Pagliarini V, Pieraccioli M, Caggiano C, Sette C. (2019) Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors. Cells. Dec 18;9(1).
11. Caggiano C, Pieraccioli M, Panzeri V, Sette C*, Bielli P*. (2019) c-MYC empowers transcription and productive splicing of the oncogenic splicing factor Sam68 in cancer. Nucleic Acids Res. 47(12):6160-6171.
12. Naro C, Pellegrini L, Jolly A, Farini D, Cesari E, Bielli P, de la Grange P, Sette C. (2019) Functional Interaction between U1snRNP and Sam68 Insures Proper 3' End Pre-mRNA Processing during Germ Cell Differentiation. Cell Rep. 26(11):2929-2941.
13. Bielli P, Di Stasi SM, Sette C. (2018) The emerging role of PTBP1 in human cancer: novel prognostic factor in non-muscle invasive bladder cancer. Transl Androl Urol. 7(Suppl 6):S765-S767.
14. Bielli P, Panzeri V, Lattanzio R, Mutascio S, Pieraccioli M, Volpe E, Pagliarulo V, Piantelli M, Giannantoni A, Di Stasi SM, Sette C. The splicing factor PTBP1 promotes expression of oncogenic splice variants and predicts poor prognosis in patients with non-muscle invasive bladder cancer. Clinical Cancer Res. 4:5422-5432.
15. Pascarella A, Ferrandino G, Credendino SC, Moccia C, D'Angelo F, Miranda B, D'Ambrosio C, Bielli P, Spadaro O, Ceccarelli M, Scaloni A, Sette C, De Felice M, De Vita G, Amendola E (2018) DNAJC17 is localized in nuclear speckles and interacts with splicing machinery components. Sci Rep. 8:7794.
16. Passacantilli I, Panzeri V, Bielli P, Farini D, Pilozzi E, Fave GD, Capurso G, Sette C (2017) Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. Cell Death Dis. 8:e3168.
17. Bielli P, Sette C (2017) Analysis of in vivo Interaction between RNA Binding Proteins and Their RNA Targets by UV Cross-linking and Immunoprecipitation (CLIP) Method. Bio Protocol. 7(10).
18. Naro C, Jolly A, Di Persio S, Bielli P, Setterblad N, Alberdi AJ, Vicini E, Geremia R, De la Grange P, Sette C (2017) An Orchestrated Intron Retention Program in Meiosis Controls Timely Usage of Transcripts during Germ Cell Differentiation. Developmental Cell.; 41(1):82-93.e4
19. Nazio F, Carinci M, Valacca C, Bielli P, Strappazzon F, Antonioli M, Ciccosanti F, Rodolfo C, Campello S, Fimia GM, Sette C, Bonaldo P, and Cecconi F (2016) Fine-tuning of ULK1 mRNA and protein levels is required for autophagy oscillation. J Cell Biol 215(6): 841-856.
20. La Rosa P, Bielli P, Compagnucci C, Cesari E, Volpe E, Farioli Vecchioli S, and Sette C (2016) Sam68 promotes self-renewal and glycolytic metabolism in mouse neural progenitor cells by modulating Aldh1a3 pre-mRNA 3'-end processing. Elife, pii: e20750. doi: 10.7554/eLife.20750.
21. Annibalini G*, Bielli P*, De Santi M, Agostini D, Guescini M, Sisti D, Contarelli S, Brandi G, Villarini A, Stocchi V, Sette C and Barbieri E (2016) MIR retroposon exonization promotes evolutionary variability and generates species-specific expression of IGF-1 splice variants. Biochim Biophys Acta 1859(5): 757-768. *co-first author.
22. Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G, Fave GD Sette C (2015) Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene 35: 2031-2039.
23. Naro C, Bielli P, Pagliarini V and Sette C (2015) The interplay between DNA damage response and RNA processing: the unexpected role of splicing factors as gatekeepers of genome stability. Front Genet 6:142.
24. Bielli P, Bordi M, Biasio VD and Sette C (2014) Regulation of BCL-X splicing reveals a role for the polypyrimidine tract binding protein (PTBP1/hnRNP I) in alternative 5' splice site selection. Nucleic Acids Res 42(19): 12070-12081.
25. Bielli P, Busà R, Di Stasi SM, Munoz MJ, Botti F, Kornbhlitt AR and Sette C (2014) The transcriptional factor FBI-1 regulates SAM68-mediated BCL-X alternative splicing and apoptosis. EMBO Reports 5(4): 419-427.
26. Cappellari M, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, Saarikettu J, Silvennoinen O and Sette C (2014) The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells. Oncogene 33: 3794-3802.
27. Nazio F, Strappazzon F, Antonioli M, Bielli P, Cianfanelli V, Bordi M, Gretzmeier C, Dengjel J, Piacentini M, Fimia GM and Cecconi F (2013) mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol 15(4): 406-416.
28. Fausti F, Di Agostino S, Cioce M, Bielli P, Sette C, Pandolfi PP, Oren M, Sudol M, Strano S and Blandino G (2013) ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence. Cell Death Differ 20(11): 1498-1509.
29. Bielli P, Busà R, Paronetto MP and Sette C (2011) The RNA binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer 18(4): R91-R102.
30. Pedrotti S, Bielli P, Paronetto MP, Ciccosanti F, Fimia GMR, Stamm S, Manley JL and Sette C (2010) The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. Embo J 29: 1235-1247.
31. Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni F, Geremia R and Sette C (2008) Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 29(12): 2279-2288.
32. Casavola EC, Catucci A, Bielli P, Di Pentima A, Porcu G, Pennestri M, Cicero DO and Ragnini-Wilson A (2008) Ypt32p and Mlc1p bind within the vesicle binding region of the class V myosin Myo2p globular tail domain. Mol Microbiol 67(5): 1051-1066.
33. Bielli P., Casavola EC, Biroccio A, Urbani A and Ragnini-Wilson A (2006) GTP driver myosin light chain 1 interaction with the class V myosin Myo2 IQ motifs via a Sec2 RabGEF-mediated patrhway. Mol Microbiol 59:1576-1590.
34. Melino S., Pennestri M., Santoprete A., Bielli P., Paci M., Ragnini-Wilson A. and Cicero DO (2005) Letter to the Editor: Assignment of the 1H, 13C and 15N resonances of Mlc1p from Saccharomyces cerevisiae. Journal of Biomolecular NMR 31(4): 367-368.
35. Wagner W, Bielli P, Wacha S and Ragnini-Wilson A (2002) Mlc1p promotes septum closure during cytokinesis via the IQ motifs of the vesicle motor Myo2. Embo J 23: 6397-6408.
36. Bielli P and Calabrese L (2002) Structure to function relationships in ceruloplasmin: a “moonlighting” protein. Cell Mol Life Sci 59: 1413-1427.
37. Bielli P, Bellenchi GC and Calabrese L (2001) Site-directed mutagenesis of human ceruloplasmin: production of a proteolytically stable protein and structure-activity relationships of type 1 sites. J Biol Chem 276: 2678-2685.
38. Bonaccorsi di Patti MC, Bellenchi GC, Bielli P and Calabrese L (1999) Release of highly active Fet3 from membranes of the yeast Pichia pastoris by limited proteolysis. Arch Biochem Biophys 372: 295-299.
Si autorizza al trattamento dei dati personali in accordo con quanto stabilito ai sensi dell’art. 13 del D. Lgs. 193/2003 e dell’art. 13 GDPR 679/16.
02/05/2024